Passage Bio (PASG) Expected to Announce Earnings on Tuesday

Posted by Editorial Team on May 12th, 2025

Passage Bio (NASDAQ:PASG – Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Passage Bio (NASDAQ:PASG – Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. On average, analysts expect Passage Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Passage Bio Trading Down 5.0%

NASDAQ:PASG opened at $0.33 on Monday. Passage Bio has a 1-year low of $0.30 and a 1-year high of $1.55. The business’s 50-day moving average price is $0.38 and its two-hundred day moving average price is $0.54. The firm has a market capitalization of $20.46 million, a price-to-earnings ratio of -0.28 and a beta of 1.68.

Insiders Place Their Bets

In other news, major shareholder Orbimed Advisors Llc sold 78,049 shares of Passage Bio stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $0.34, for a total transaction of $26,536.66. Following the completion of the transaction, the insider now directly owns 6,807,523 shares in the company, valued at approximately $2,314,557.82. The trade was a 1.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 233,660 shares of company stock valued at $77,723. 5.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Chardan Capital lowered their price target on Passage Bio from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, March 4th.

Read Our Latest Report on Passage Bio

Passage Bio Company Profile

(Get Free Report)

Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.